Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Kapikachhu (Mucuna pruriens) contains 3-7% L-DOPA by weight, a direct precursor to dopamine that crosses the blood-brain barrier. This leguminous plant has been used in Ayurveda for neurological conditions and reproductive health support.
Origin & History
Kapikachhu (Mucuna pruriens) is a tropical legume native to Africa and tropical Asia, with seeds serving as the primary medicinal part containing 3.1–6.1% L-DOPA. The seeds are processed into fine powder (churna) or medicated confections (pak) after traditional purification (shodhana) methods.
Research Narrative (Provisional)
The research dossier explicitly states that search results lack specific human clinical trials, RCTs, or meta-analyses with PubMed PMIDs. No study designs, sample sizes, or clinical outcomes are provided in the available literature.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
{"macronutrients": {"protein": "20-29% by weight", "fiber": "Approximately 5-10% by weight"}, "micronutrients": {"minerals": {"calcium": "0.1-0.2% by weight", "iron": "0.01-0.02% by weight", "phosphorus": "0.4-0.6% by weight"}, "vitamins": {"vitamin_C": "Trace amounts"}}, "bioactive_compounds": {"L-DOPA": "3-7% by weight", "antioxidants": "Up to 40% free radical scavenging activity"}, "bioavailability_notes": "L-DOPA content is significant for neurological health support, but bioavailability may vary based on preparation and individual metabolism."}
Reported Mechanism (Provisional)
L-DOPA in kapikachhu crosses the blood-brain barrier and converts to dopamine via aromatic L-amino acid decarboxylase. This increases dopamine levels in the substantia nigra and striatum, supporting motor function and neurological pathways. Secondary compounds like serotonin and nicotine alkaloids may provide additional neurotransmitter modulation.
Clinical Narrative (Provisional)
Limited clinical trials exist for Mucuna pruriens, with most evidence from small pilot studies in Parkinson's disease patients showing improved motor symptoms. Traditional Ayurvedic literature describes use for Kampavata and Vajikarana, but lacks controlled human studies. Current research focuses primarily on L-DOPA content analysis and animal models rather than robust clinical trials. Evidence remains preliminary and requires larger, controlled studies for definitive therapeutic claims.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.